Sharekhan

AstraZeneca Pharma India Ltd

Thu 13/03/2025,15:54:48 | NSE : ASTRAZEN

₹ 7675.55-31.30 (-0.41%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 7710.00

Previous Close

₹ 7706.85

Volume

59650

Mkt Cap ( Rs. Cr)

₹19188.88

High

₹ 7970.60

Low

₹ 7584.00

52 Week High

₹ 8139.00

52 Week Low

₹ 4785.00

Book Value Per Share

₹ 271.74

Dividend Yield

0.31

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on AstraZeneca Pharma India Ltd

Your Vote -

Buy

64.58%

Hold

5.21%

Sell

30.21%

64.58%

96 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

7675.55

113

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

113

Option Chain

Analyzes market sentiment, predicts AstraZeneca Pharma India Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2

    7 Mar 2025, 5:04PM Please find the enclosed intimation of the Company as per the captioned subject for your reference.
  • AstraZeneca Pharma I - Updates

    7 Mar 2025, 5:02PM AstraZeneca Pharma India Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requi
  • AstraZeneca Pharma I - Updates

    6 Mar 2025, 3:06PM AstraZeneca Pharma India Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requi
  • AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements)\r\nRegulation

    6 Mar 2025, 3:09PM Please find the enclosed intimation of the Company as per the captioned subject for your reference.
  • AstraZeneca Pharma I - Integrated Filing (Financial)

    3 Mar 2025, 5:41PM Please find the enclosed intimation of the Company as per the captioned subject.
  • AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2

    3 Mar 2025, 1:53PM Please find the enclosed lintimation of the Company in relation to the captioned subject for your reference.
  • AstraZeneca Pharma I - Updates

    28 Feb 2025, 4:34PM AstraZeneca Pharma India Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requi
  • AstraZeneca Pharma I - Copy of Newspaper Publication

    25 Feb 2025, 5:38PM AstraZeneca Pharma India Limited has informed the Exchange about Copy of Newspaper Publication
  • AstraZeneca Pharma I - Notice Of Shareholders Meetings-XBRL

    25 Feb 2025, 3:01PM ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot
  • AstraZeneca Pharma I - Updates

    25 Feb 2025, 10:52AM AstraZeneca Pharma India Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requi
  • AstraZeneca Pharma I - Shareholders meeting

    24 Feb 2025, 5:10PM AstraZeneca Pharma India Limited has informed the Exchange regarding Notice of Postal Ballot
  • AstraZeneca Pharma I - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    24 Feb 2025, 5:07PM Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
  • AstraZeneca Pharma I - Integrated Filing- Financial

    17 Feb 2025, 6:14PM Please find the enclosed Financial Results of the Company for the quarter and nine months ended December 31, 2024.
  • AstraZeneca Pharma I - Copy of Newspaper Publication

    14 Feb 2025, 7:09PM AstraZeneca Pharma India Limited has informed the Exchange about Copy of Newspaper Publication
  • AstraZeneca Pharma I Q3 net profit jumps 95.25% at Rs 30.85 cr

    11 Feb 2025, 7:20PM The company reported standalone net profit of Rs 30.85 crore for the quarter ended December 31, 2024 as compared to Rs 15.80 crore in the same period
  • AstraZeneca Pharma I - Outcome Of The Board Meeting Held On Tuesday, February 11, 2025

    11 Feb 2025, 7:17PM Please find the enclosed document as per the captioned subject for your reference.
  • AstraZeneca Pharma I - Financial Result Updates

    11 Feb 2025, 7:13PM AstraZeneca Pharma India Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • AstraZeneca Pharma I - Press Release

    11 Feb 2025, 7:10PM Please find the enclosed document as per the captioned subject for your reference.
  • AstraZeneca Pharma I - Press Release

    11 Feb 2025, 7:05PM AstraZeneca Pharma India Limited has informed the Exchange regarding a press release dated February 11, 2025, titled ""Press Release"".
  • AstraZeneca Pharma I - Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, February 11, 2025

    11 Feb 2025, 6:44PM At the Board meeting of the Company held on Tuesday, February 11, 2025, the Board of Directors considered and approved the unaudited financial results
  • AstraZeneca Pharma I - Outcome of Board Meeting

    11 Feb 2025, 6:39PM AstraZeneca Pharma India Limited has informed the Exchange regarding Board meeting held on February 11, 2025.
  • AstraZeneca Pharma I - General Updates

    11 Feb 2025, 6:17PM AstraZeneca Pharma India Limited has informed the Exchange about General Updates
  • AstraZeneca Pharma I - General Updates

    11 Feb 2025, 5:37PM AstraZeneca Pharma India Limited has informed the Exchange about General Updates
  • AstraZeneca Pharma I - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    10 Feb 2025, 3:17PM AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • AstraZeneca Pharma I - Updates

    10 Feb 2025, 3:15PM AstraZeneca Pharma India Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure R
  • AstraZeneca Pharma I - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Feb 2025, 3:24PM Plaese find the enclosed letter of the Company with reference to the captioned subject.
  • AstraZeneca Pharma I - General Updates

    21 Jan 2025, 5:41PM AstraZeneca Pharma India Limited has informed the Exchange about General Updates
  • AstraZeneca Pharma I - Board Meeting Intimation

    20 Jan 2025, 4:57PM ASTRAZENECA PHARMA INDIA LIMITED has informed the Exchange about Board Meeting to be held on 11-Feb-2025 to inter-alia consider and approve the Unaudi
  • AstraZeneca Pharma I - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday, F

    20 Jan 2025, 4:51PM ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to con
  • AstraZeneca Pharma I has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    18 Jan 2025, 5:30PM As of December 2024, 75.00% is owned by Foreign Promoters and 25.00% by Public. <p align=justify> Institutional holds 8.13% (Insurance Companies 0.13%
  • AstraZeneca Pharma I - General Updates

    16 Jan 2025, 5:15PM AstraZeneca Pharma India Limited has informed the Exchange about General Updates
  • AstraZeneca Pharma I - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2

    16 Jan 2025, 5:17PM This is to inform that the Company has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-2
  • AstraZeneca Pharma I - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    9 Jan 2025, 7:08PM Please find the enclosed letter of the Company as per the captioned subject for your reference.
  • AstraZeneca Pharma I - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    9 Jan 2025, 7:06PM AstraZeneca Pharma India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • AstraZeneca Pharma I - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    7 Jan 2025, 12:36PM AstraZeneca Pharma India Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
  • AstraZeneca Pharma I - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    23 Dec 2024, 6:17PM Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.
  • AstraZeneca Pharma I - Shareholders meeting

    23 Dec 2024, 6:13PM AstraZeneca Pharma India Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot
  • Astrazenaca Pharma

    7 Mar 2025 , 10:52AM The company received permission from India's drug regulator to import and sell sodium zirconium cyclosilicate powder for oral suspension used in treatment of hyperkalaemia
  • AstraZeneca Pharma

    3 Mar 2025 , 12:42PM The company received permission from the Central Drugs Standard Control Organisation to import lung cancer drug
  • Astrazenaca Pharma

    17 Jan 2025 , 9:46AM Company gets approval to import the drug Eculizumab in India for selling or distributing. Eculizumab is a drug that treats rare blood diseases like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Positive
  • Astrazeneca Pharma Trade

    24 Sep 2024 , 11:58AM AstraZeneca: Company gets nod to launch cancer drug durvalumab in India.
  • AstraZeneca Pharma rises as co gets CDSCO nod

    24 Sep 2024 , 10:09AM AstraZeneca up as co gets CDSCO nod for import of Durvalumab for sale & distribution
  • AstraZenecea Pharma India

    24 Sep 2024 , 9:58AM AstraZeneca: Company gets nod to launch cancer drug durvalumab in India.
  • Astrazenca Pharma India

    27 Mar 2024 , 10:37AM The company received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilized powder for concentrate from CDSO – Positive read through for the stock.
  • Astrazeneca Pharma

    21 Dec 2023 , 10:41AM The company will launch Enhertu in January 2024 in India. Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2- based regimen. (Positive)
  • AstraZeneca Pharma

    25 Jul 2023 , 11:01AM AstraZeneca Pharma India Ltd. has received permission to import pharmaceutical formulations of new drug for sale or distribution in Form CT-20 from the Drug Controller General of India for Dapagliflozin tablets 10 mg. Dapagliflozin Tablets is used to treat heart failure in adults. Positive.
  • AstraZeneca Pharma India

    2 Jun 2023 , 10:01AM The company has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Tremelimumab (Imjudo) Concentrate for solution for infusion 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route. Through this approval, Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).
  • Astrazenca Pharma India Ltd

    4 May 2023 , 10:47AM The company said it has been granted approval by DCGI in India to import and market trastuzumab deruxtecan used in the treatment of select 'HER-2 positive' breast cancer. Globally, trastuzumab deruxtecan is approved in more than 40 countries, including the U.S., for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. Breast cancer market was worth USD 20.2 billion, globally, in 2019 and was dominated by sales of therapies targeting HER-2 or CDK4/6 (68.0% of sales). Despite the likely entry of competition, it is estimated that the global breast cancer market will grow at 9.0% annually to USD 47.7 billion over CY19-CY29. Zydus Lifesciences has Ujvira (trastuzumab Emtansine - biosimilar) being marketed in India since 2021. Even Dr. Reddy’s has Hervycta (Tanezumab biosimilar commercialized in India) launched in India, since 2018. Positive read through for AstraZeneca Pharma India. We do not have it under coverage
  • Asterzenca Pharma

    28 Nov 2022 , 9:09AM Asterzenca Pharma: The company has received an import and market permission in Form CT-20 (Subsequent New Drug Approval) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for Dapagliflozin (Forxiga) tablets of 10 mg - additional indication. Through this approval, the Company is permitted to deal in Dapagliflozin (Forxiga) tablets of 10 mg in additional/expanded indication to reduce the risk of sustained eGFR and kidney disease, cardiovascular death and hospitalization for heart failure in adult with chronic kidney disease at risk of progression with condition that:- it is indicated in adults for the treatment of patients of chronic kidney disease (CKD) up to eGFR of greater than or equal to 25ml/min/1.73m2 – Positive read through for the stock.
  • Astrazeneca Pharma receives Import and Market Permission in Form CT-20

    27 Sep 2021 , 10:40AM Astrazeneca Pharma India receives DCGI approval to import, market Selumetinib capsules
  • AstraZeneca Pharma gets import and market permission for Benralizumab

    21 Dec 2020 , 11:36AM AstraZeneca Pharma India receives import and market Permission in Form CT-20
  • AztraZeneca to launch oncology drug Calquence in India

    16 Oct 2020 , 12:44PM Launch of Acalabrutinib 100mg capsules
  • AstraZeneca Pharma hits fresh record high

    4 Sep 2020 , 1:49PM AstraZeneca surges by 5% to Rs. 3900, in weak market
  • AstraZeneca gets import and market permission for Olaparib Film-Coated tablets

    19 Aug 2020 , 1:44PM AstraZeneca Pharma receives Import and Market permission in Form CT-20
  • Astrazeneca Pharma India

    6 Jul 2020 , 11:44AM Gets permission to import and market in Form CT-20 from the Drug Controller General of India for Dapagliflozin film coated tablet 10 mg. The drug is used in the treatment of heart failure with reduced ejection fraction. The permission is positive as it would aid topline growth.
  • AstraZeneca gets DCGI approval for type 2 diabetes drug

    26 Sep 2019 , 12:40PM AstraZeneca Pharma India receives Import and Market permission in Form 45 from the Drugs Controller General of India for FDC
  • AstraZeneca gets DGCI nod for cancer drug

    17 Aug 2018 , 12:05PM AstraZeneca gets import and market permission in Form 45 from the Drugs Controller General of India
  • Astrazeneca to invest $90 mn over next 5 years in India

    18 Apr 2018 , 11:48AM Astrazeneca rises over 5% at Rs1045.50, after parent, AstraZeneca, announces its decision of further investing $90 million over the next 5 years in India
  • AstraZeneca gets nod for importing diabetes drug

    18 Oct 2017 , 12:29PM AstraZeneca rises over 4% to Rs989.8, after receiving approval from the Drug Controller General of India to market diabetes drug

Key fundamentals

Evaluate the intrinsic value of AstraZeneca Pharma India Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 711.92 588.69 511.39 456.17 364.44
Liabilities 711.92 588.69 511.39 456.17 364.44
Equity 5 5 5 5 5
Gross Profit 184.45 165.12 86.18 135.47 120.7
Net Profit 161.51 99.29 61.6 93.3 72.21
Cash From Operating Activities 27.87 58.29 100.8 104.78 87.42
NPM(%) 12.46 9.89 7.64 11.46 8.68
Revenue 1295.53 1002.97 805.6 813.56 831.81
Expenses 1111.08 837.85 719.42 678.09 711.11
ROE(%) 23.77 14.61 9.06 13.73 10.62

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
05 Jul 2024 24 1200 0.31 6432.8
07 Jul 2022 8 400 0.31 2639.1
18 Aug 2021 2 100 0.31 3364.65
20 Aug 2020 2 100 0.31 3379.3
20 Aug 2019 1 50 0.31 1956.35
07 Jul 2011 10 500 0.31 1319.85
06 May 2010 10 500 0.31 881.45
29 Apr 2009 15 750 0.31 485.6
11 Apr 2008 15 750 0.31 547.9
22 Mar 2007 12 600 0.31 595
60 600 0.31 610.25
12 Apr 2006 20 200 0.31 3131.3
18 Mar 2005 50 500 0.31 1594.2
16 Apr 2004 3.9 39 0.31 1089.15
15 May 2002 0 30 0.31 362.45
18 Jun 2001 0 40 0.31 429.85
11 Aug 2000 0 5 0.31 294.3
0 35 0.31 205
0 33 0.31 272.1

Peers

Other companies within the same industry or sector that are comparable to AstraZeneca Pharma India Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 4371.89 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 15930.59 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 8211.24 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 15021.17 -239.30 0.00

Company Info

YEAR EVENTS 1979 - The Company was incorporated on 11th July, and the Certificate of Commencement of Business was obtained on 6th November, 1979. It was promoter jointly by Astra Pharmaceuticals AB, Sweden (Astra) and IDL Chemicals Ltd., Hyderabad (IDL). 1980 - The Company entered into a technical collaboration with Astra Pharmaceuticals AB, Sweden for the supply for information and know-how and all manufacturing process and technical data for the manufacture of basic drugs, formulations, fine chemicals and industrial chemicals. - The Company undertook to set up a project at Yelahanka, Bangalore, for the manufacture of basic drugs, formulations, fine and industrial chemicals. Pharmaceuticals and chemicals plant was commissioned in February 1982. 1982 - 2,000 shares issued to promoters, etc. 24,98,000 shares issued at par; 6,43,235 shares each allotted to Astra Pharmaceuticals AB, Sweden and IDL Chemicals, Ltd.; 3,78,830 shares allotted to Indian directors, shareholders and employees, shareholders and employees, etc. of the company and also that of IDL Chemicals, Ltd. and 8,32,700 shares offered for public subscription during February-March, 1982. 1988 - The Company launched `SENSORCAINE', a long acting local anaesthetic for use in surgical anaesthesia and introduced `THEOBRIC', a combination branco dilator for asthma. The Company also planned to launch new products based on original research of Astra in the fields of peptic ulcer, hypertension and asthma. - The Company launched during the year `RESTOMYCIN', an antibiotic `BROMENYL', a cough expectorant and `FEBRAFEN' a pain and fever reliever. - The company was also in the process of creating in-house facilities for the manufacture of products based on inhalation therapy and formulation therapy and formulations based on prostaglandins. - The Company launched `PROSTODIN', the first protagladin with an important indication for postpartum haemorage, etc. Several new products were launched during the year, namely, SELOPRES, BETALOC DURULES, TRIPRES, SENSORCAINE SPINAL and BRICANYL NEBULISING SOLUTION. It also launched products based on inhalation therapy such as `PULMICORTINHALER' BRICANYL INHALER and SPACEHALER. 1991 - The Company launched a product in the Prostaglandins range `PIMIPROST' for the promotion of safe motherhood. 1992 - The Company launched Prostaglandin `Cerviprime Gel' for preinduction cervical ripening and `Plendil' a new generation calcium antagonist. The Company proposed to launch `Ramace', `Rhinocort' and `Imdur'. 1994 - Several new products were launched during the year, namely, Ramace and Imdur, which strengthen the cardiovascular range of products. Similarly Rhinocort was introduced which is in the range of respiratory care products. 1995 - 25,00,000 bonus shares issued in prop. 1:1. 1996 - Two new line of extension namely `Jumbo' pack of Pulmicort & Bricanyl Inhalers 400 metered doses were introduced in the respiratory group. A low dose aspirin formation to correct thromboembolic disorders was launched. Also Imdur 30 mg to support Imdur 60 mg was introduced. 1997 - A range of new products viz., Xylocaine Spray in pain control segment, Stop-it in Anti-infective segment, Mimbid in NSAID segment, Linctus-D and Rhinocort Aqua in Respiratory segment, Rejois in Maternal health care segment and Cellubril, a stool softner. - The company established state-of-the-art production facilities for aerosols and soft gelatin capsules near its formulations plant. - A joint venture between Astra AB of Sweden and IDL Industries of the Hindujas, Astra-IDL has been the subject of a prolonged litigation between the two promoters. - A joint venture between the US $ 7-billion Swedish pharmaceutical major Astra AB and IDL Industries of the Hindujas. 1998 - Wipro, Honda Siel Power Products, and Astra-IDL have been conferred the Analyst Awards, by The Institute of Chartered Financial Analysts of India (ICFAI). - Astra had set up a 100 per cent research facility in Bangalore three years ago. 1999 - Even as the Hindujas continue to seek new alignments to replace multinational AstraZeneca in their joint venture Astra-IDL Ltd. 2000 - UB's 100 per cent subsidiary, UB Bioteck, has tied up with Astra IDL Ltd to market its newly-patented anti-obesity nutraceutical. - Mr. D.E. Udwadia, Director, has been appointed as the Chairman. 2001 - Crisil has placed the `FAA' rating on the fixed deposit programme of the company on a `rating watch with positive implications'. - The Company upon the acquisition, Astra, Swden now holds 51.50 per cent of the company's issued and paid-up equity shares capital. The company is therefore a subsidiary of Astra, Swden and has become a part of the worldwide AstraZeneca Group. - The Managing Director, Mr. A.R. Hegde, has resigned from the company. - Astra-IDL Ltd will be renamed AstraZeneca Pharma India Ltd and Mr Lars Walan, recently designated Managing director, will take over on April 2 from Mr. A.R. Hegde, MD, who has resigned. 2002 -Ties up with Avestha for research on discovering drug for tuberculosis. -Makes an open offer to acquire the balance 21,75,050 equity shares of Astrazeneca pharma India Ltd representing 43% stake. -Government okays FDI proposal for the company and Tata Homefinance from 56.69% to 100% accounting for Rs.82 crs. -Astra Pharma acquires 32800 equity shares of Astrazeneca. 2003 -Astra Pharma and Astrazeneca jointly acquires less than 4% additional equity Astrazeneca Pharma India Ltd. -Sri Tom McKillop, inaugurates R & D centre in Bangalore at a cost of $40 million. -Approaches Union government for Exclusive Marketing Rights for new two generation anti-cancer drugs. -Astrazeneca Pharma India Limited Board accepts resignation of Mr. J G Zetterberg, Director, effective from the close of May 05, 2004. 2006 -AstraZeneca acquires Eli Lilly's Vancocin brand -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -AstraZeneca Pharma India Ltd has appointed Mr. Ruud Dobber as Director of the Company. 2010 - AstraZeneca Pharma and biopharmaceutical company Bristol-Myers Squibb launched their 9-month-old diabetes drug Onglyza in India - the biggest market for the drug.Onglyza, or saxagliptin, is used to treat type 2 diabetes in adults. - AstraZeneca Pharma India Ltd has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company. 2011 -AstraZeneca Halts Late-Stage Trial of Prostate Cancer Medicine Zibotentan -Appointment of Mr. Himanshu Agarwal as the CFO of the Company 2012 -AstraZeneca Excellence in Chemistry Awards 2011 -AstraZeneca and Cellworks Collaborate to find new Treatment for Tuberculosis -AstraZeneca launches its patented life-saving heart drug BRILINTAr (Ticagrelor) in India 2013 -AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets -AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment. 2014 -AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration (FDA) approved FARXIGAT (dapagliflozin). -AstraZeneca and MRC enter strategic collaboration to create new centre for early drug discovery in Cambridge, UK . -AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291 -The Registered Office of the Company has been shifted from 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024 to Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045. 2015 -AstraZeneca Pharma India Limited and Dr Reddy's Laboratories Limited enter distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 Diabetes -AstraZeneca Pharma launches type-2 diabetes treatment drug -BRILIQUE (ticagrelor) receives positive European Union CHMP opinion for extended treatment of patients with a history of heart attack -AstraZeneca completes acquisition of ZS Pharma -AstraZeneca opens new manufacturing facility to support continued growth in Russia 2017 -AstraZeneca Pharma receives import permission for inhaler powder. -AstraZeneca Pharma receives approval for Osimertinib Tablet. 2018 -AZPIL receives permission for Durvalumab from Drug Controller General of India. 2021 -AstraZeneca's Partners With DocOn to Digitise Healthcare Clinics Across India. -AstraZeneca in collaboration with Rajiv Gandhi Cancer Institute announces the launch of Project Chariot to help diagnose and treat patients with Chronic Lymphocytic Leukemia (CLL). -AstraZeneca launches Clinical Data and Insights division in India. 2022 -AstraZeneca Pharma gets CDSCO nod for Dapagliflozin tablets. 2023 -AstraZeneca Inaugurates "Centre of Excellence" at Manipal Hospital Goa for Severe Asthma Patients. -AstraZeneca India partners with Roche Diagnostics India to improve diagnostic testing for breast cancer patients. -Govt. of Karnataka signs MoU with AstraZeneca India to accelerate Lung Cancer testing. 2024 -AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announced a collaboration for the exclusive distribution of the asthma medication brand, Symbicort, in India. -AstraZeneca India receives Central Drugs Standard Control Organisation approval for Durvalumab for specified additional indication. -AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru. -AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India for critical bleeding conditions associated with use of novel anticoagulants.

YEAR EVENTS 1979 - The Company was incorporated on 11th July, and the Certificate of Commencement of Business was obtained on 6th November, 1979. It was promoter jointly by Astra Pharmaceuticals AB, Sweden (Astra) and IDL Chemicals Ltd., Hyderabad (IDL). 1980 - The Company entered into a technical collaboration with Astra Pharmaceuticals AB, Sweden for the supply for information and know-how and all manufacturing process and technical data for the manufacture of basic drugs, formulations, fine chemicals and industrial chemicals. - The Company undertook to set up a project at Yelahanka, Bangalore, for the manufacture of basic drugs, formulations, fine and industrial chemicals. Pharmaceuticals and chemicals plant was commissioned in February 1982. 1982 - 2,000 shares issued to promoters, etc. 24,98,000 shares issued at par; 6,43,235 shares each allotted to Astra Pharmaceuticals AB, Sweden and IDL Chemicals, Ltd.; 3,78,830 shares allotted to Indian directors, shareholders and employees, shareholders and employees, etc. of the company and also that of IDL Chemicals, Ltd. and 8,32,700 shares offered for public subscription during February-March, 1982. 1988 - The Company launched `SENSORCAINE', a long acting local anaesthetic for use in surgical anaesthesia and introduced `THEOBRIC', a combination branco dilator for asthma. The Company also planned to launch new products based on original research of Astra in the fields of peptic ulcer, hypertension and asthma. - The Company launched during the year `RESTOMYCIN', an antibiotic `BROMENYL', a cough expectorant and `FEBRAFEN' a pain and fever reliever. - The company was also in the process of creating in-house facilities for the manufacture of products based on inhalation therapy and formulation therapy and formulations based on prostaglandins. - The Company launched `PROSTODIN', the first protagladin with an important indication for postpartum haemorage, etc. Several new products were launched during the year, namely, SELOPRES, BETALOC DURULES, TRIPRES, SENSORCAINE SPINAL and BRICANYL NEBULISING SOLUTION. It also launched products based on inhalation therapy such as `PULMICORTINHALER' BRICANYL INHALER and SPACEHALER. 1991 - The Company launched a product in the Prostaglandins range `PIMIPROST' for the promotion of safe motherhood. 1992 - The Company launched Prostaglandin `Cerviprime Gel' for preinduction cervical ripening and `Plendil' a new generation calcium antagonist. The Company proposed to launch `Ramace', `Rhinocort' and `Imdur'. 1994 - Several new products were launched during the year, namely, Ramace and Imdur, which strengthen the cardiovascular range of products. Similarly Rhinocort was introduced which is in the range of respiratory care products. 1995 - 25,00,000 bonus shares issued in prop. 1:1. 1996 - Two new line of extension namely `Jumbo' pack of Pulmicort & Bricanyl Inhalers 400 metered doses were introduced in the respiratory group. A low dose aspirin formation to correct thromboembolic disorders was launched. Also Imdur 30 mg to support Imdur 60 mg was introduced. 1997 - A range of new products viz., Xylocaine Spray in pain control segment, Stop-it in Anti-infective segment, Mimbid in NSAID segment, Linctus-D and Rhinocort Aqua in Respiratory segment, Rejois in Maternal health care segment and Cellubril, a stool softner. - The company established state-of-the-art production facilities for aerosols and soft gelatin capsules near its formulations plant. - A joint venture between Astra AB of Sweden and IDL Industries of the Hindujas, Astra-IDL has been the subject of a prolonged litigation between the two promoters. - A joint venture between the US $ 7-billion Swedish pharmaceutical major Astra AB and IDL Industries of the Hindujas. 1998 - Wipro, Honda Siel Power Products, and Astra-IDL have been conferred the Analyst Awards, by The Institute of Chartered Financial Analysts of India (ICFAI). - Astra had set up a 100 per cent research facility in Bangalore three years ago. 1999 - Even as the Hindujas continue to seek new alignments to replace multinational AstraZeneca in their joint venture Astra-IDL Ltd. 2000 - UB's 100 per cent subsidiary, UB Bioteck, has tied up with Astra IDL Ltd to market its newly-patented anti-obesity nutraceutical. - Mr. D.E. Udwadia, Director, has been appointed as the Chairman. 2001 - Crisil has placed the `FAA' rating on the fixed deposit programme of the company on a `rating watch with positive implications'. - The Company upon the acquisition, Astra, Swden now holds 51.50 per cent of the company's issued and paid-up equity shares capital. The company is therefore a subsidiary of Astra, Swden and has become a part of the worldwide AstraZeneca Group. - The Managing Director, Mr. A.R. Hegde, has resigned from the company. - Astra-IDL Ltd will be renamed AstraZeneca Pharma India Ltd and Mr Lars Walan, recently designated Managing director, will take over on April 2 from Mr. A.R. Hegde, MD, who has resigned. 2002 -Ties up with Avestha for research on discovering drug for tuberculosis. -Makes an open offer to acquire the balance 21,75,050 equity shares of Astrazeneca pharma India Ltd representing 43% stake. -Government okays FDI proposal for the company and Tata Homefinance from 56.69% to 100% accounting for Rs.82 crs. -Astra Pharma acquires 32800 equity shares of Astrazeneca. 2003 -Astra Pharma and Astrazeneca jointly acquires less than 4% additional equity Astrazeneca Pharma India Ltd. -Sri Tom McKillop, inaugurates R & D centre in Bangalore at a cost of $40 million. -Approaches Union government for Exclusive Marketing Rights for new two generation anti-cancer drugs. -Astrazeneca Pharma India Limited Board accepts resignation of Mr. J G Zetterberg, Director, effective from the close of May 05, 2004. 2006 -AstraZeneca acquires Eli Lilly's Vancocin brand -Company has splits its Face value of Shares from Rs 10 to Rs 2 2007 -AstraZeneca Pharma India Ltd has appointed Mr. Ruud Dobber as Director of the Company. 2010 - AstraZeneca Pharma and biopharmaceutical company Bristol-Myers Squibb launched their 9-month-old diabetes drug Onglyza in India - the biggest market for the drug.Onglyza, or saxagliptin, is used to treat type 2 diabetes in adults. - AstraZeneca Pharma India Ltd has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company. 2011 -AstraZeneca Halts Late-Stage Trial of Prostate Cancer Medicine Zibotentan -Appointment of Mr. Himanshu Agarwal as the CFO of the Company 2012 -AstraZeneca Excellence in Chemistry Awards 2011 -AstraZeneca and Cellworks Collaborate to find new Treatment for Tuberculosis -AstraZeneca launches its patented life-saving heart drug BRILINTAr (Ticagrelor) in India 2013 -AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets -AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment. 2014 -AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration (FDA) approved FARXIGAT (dapagliflozin). -AstraZeneca and MRC enter strategic collaboration to create new centre for early drug discovery in Cambridge, UK . -AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291 -The Registered Office of the Company has been shifted from 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024 to Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045. 2015 -AstraZeneca Pharma India Limited and Dr Reddy's Laboratories Limited enter distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 Diabetes -AstraZeneca Pharma launches type-2 diabetes treatment drug -BRILIQUE (ticagrelor) receives positive European Union CHMP opinion for extended treatment of patients with a history of heart attack -AstraZeneca completes acquisition of ZS Pharma -AstraZeneca opens new manufacturing facility to support continued growth in Russia 2017 -AstraZeneca Pharma receives import permission for inhaler powder. -AstraZeneca Pharma receives approval for Osimertinib Tablet. 2018 -AZPIL receives permission for Durvalumab from Drug Controller General of India. 2021 -AstraZeneca's Partners With DocOn to Digitise Healthcare Clinics Across India. -AstraZeneca in collaboration with Rajiv Gandhi Cancer Institute announces the launch of Project Chariot to help diagnose and treat patients with Chronic Lymphocytic Leukemia (CLL). -AstraZeneca launches Clinical Data and Insights division in India. 2022 -AstraZeneca Pharma gets CDSCO nod for Dapagliflozin tablets. 2023 -AstraZeneca Inaugurates "Centre of Excellence" at Manipal Hospital Goa for Severe Asthma Patients. -AstraZeneca India partners with Roche Diagnostics India to improve diagnostic testing for breast cancer patients. -Govt. of Karnataka signs MoU with AstraZeneca India to accelerate Lung Cancer testing. 2024 -AstraZeneca Pharma India Ltd and Mankind Pharma Ltd announced a collaboration for the exclusive distribution of the asthma medication brand, Symbicort, in India. -AstraZeneca India receives Central Drugs Standard Control Organisation approval for Durvalumab for specified additional indication. -AstraZeneca and Vaayu Chest & Sleep Center collaborate to enhance respiratory care for severe asthma patients in Bengaluru. -AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India for critical bleeding conditions associated with use of novel anticoagulants.

Read More

Parent Organisation

AstraZeneca Pharma India Ltd.

Founded

11/07/1979

Managing Director

NSE Symbol

ASTRAZENEQ

FAQ

The current price of AstraZeneca Pharma India Ltd is ₹ 7675.55.

The 52-week high for AstraZeneca Pharma India Ltd is ₹ 7970.60 and the 52-week low is ₹ 7584.00.

The market capitalization of AstraZeneca Pharma India Ltd is currently ₹ 19188.88. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy AstraZeneca Pharma India Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in AstraZeneca Pharma India Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase AstraZeneca Pharma India Ltd shares.

The CEO of AstraZeneca Pharma India Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT